(MEDPAGE today) – The FDA approved on Tuesday to Mirdmeetinib (Gomekli) for adults and children between the ages of 2 and over with the nervous tuft 1 (NF1). Approval of the mek inhibitor is specifically for patients who suffer from a tumor of the bouquet tumor …
